Predictive Oncology Valuation
| POAI Stock | USD 1.69 0.01 0.60% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Predictive Oncology holds a recent Real Value of $2.51 per share. The prevailing price of the company is $1.69. Our model determines the value of Predictive Oncology from analyzing the company fundamentals such as Return On Equity of -0.93, shares owned by insiders of 3.55 %, and Current Valuation of 1.2 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Predictive Oncology's valuation include:
Price Book 0.8645 | Enterprise Value 1.2 M | Enterprise Value Ebitda (0.1) | Price Sales 4.017 | Enterprise Value Revenue 0.7188 |
Undervalued
Today
Please note that Predictive Oncology's price fluctuation is dangerous at this time. Calculation of the real value of Predictive Oncology is based on 3 months time horizon. Increasing Predictive Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Predictive Oncology is useful when determining the fair value of the Predictive stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Predictive Oncology. Since Predictive Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Predictive Stock. However, Predictive Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.69 | Real 2.51 | Target 5.0 | Hype 1.74 | Naive 1.31 |
The real value of Predictive Stock, also known as its intrinsic value, is the underlying worth of Predictive Oncology Company, which is reflected in its stock price. It is based on Predictive Oncology's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Predictive Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Predictive Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Predictive Oncology helps investors to forecast how Predictive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Predictive Oncology more accurately as focusing exclusively on Predictive Oncology's fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Predictive Oncology's intrinsic value based on its ongoing forecasts of Predictive Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Predictive Oncology's closest peers. When choosing an evaluation method for Predictive Oncology, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Predictive Oncology Investments |
|
Predictive Valuation Trend
Knowing Predictive Oncology's actual value is paramount for traders to make sound investment determinations. Predictive Oncology's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Predictive Oncology's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Predictive Oncology's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Predictive Market Cap
Predictive Oncology is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is at this time estimated at about 95.36 Billion. Predictive Oncology adds roughly 6.73 Million in market capitalization claiming only tiny portion of equities under Health Care industry.Predictive Oncology Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Predictive Oncology's current stock value. Our valuation model uses many indicators to compare Predictive Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Predictive Oncology competition to find correlations between indicators driving Predictive Oncology's intrinsic value. More Info.Predictive Oncology is rated below average in price to book category among related companies. It is regarded fourth in price to sales category among related companies fabricating about 4.65 of Price To Sales per Price To Book. As of now, Predictive Oncology's Price To Sales Ratio is decreasing as compared to previous years.Comparative valuation analysis is a catch-all model that can be used if you cannot value Predictive Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Predictive Oncology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Predictive Oncology's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Predictive Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Predictive Oncology and how it compares across the competition.
About Predictive Oncology Valuation
The stock valuation mechanism determines the current worth of Predictive Oncology on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Predictive Oncology. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Predictive Oncology based exclusively on its fundamental and basic technical indicators. By analyzing Predictive Oncology's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Predictive Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Predictive Oncology. We calculate exposure to Predictive Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Predictive Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 433.4 K | 523.2 K | |
| Pretax Profit Margin | (7.86) | (8.25) | |
| Operating Profit Margin | (7.82) | (8.21) | |
| Net Loss | (7.86) | (8.25) | |
| Gross Profit Margin | 0.24 | 0.45 |
8 Steps to conduct Predictive Oncology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Predictive Oncology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Predictive Oncology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Predictive Oncology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Predictive Oncology's revenue streams: Identify Predictive Oncology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Predictive Oncology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Predictive Oncology's growth potential: Evaluate Predictive Oncology's management, business model, and growth potential.
- Determine Predictive Oncology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Predictive Oncology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Predictive Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Predictive Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4 M |
Predictive Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Predictive Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Predictive we look at many different elements of the entity such as Predictive's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Predictive Oncology's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Predictive Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Predictive Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Predictive Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Predictive Oncology's worth.When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Predictive Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.48) | Revenue Per Share 0.443 | Quarterly Revenue Growth (0.08) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.